

12m Results 2023

 Opinion ⁽¹⁾: Below expectations

 Impact ⁽¹⁾: We lower our estimates

Luis Esteban Arribas, CESGA – luis.esteban@institutodeanalistas.com

+34 915 904 226

Pangaea Oncology (PANG) is a small Spanish biotech company (Zaragoza), specialising in differentiated cancer diagnosis and treatment and corporate services (molecular diagnostics and biomarker discovery for the pharmaceutical industry). It is run by a prestigious medical team that includes its founders (c.13% of capital). The Villagrà family (Villagrà) and GPI (Mayoral) are reference shareholders.

Market Data

Market Cap (Mn EUR and USD)	53.4	57.0
EV (Mn EUR and USD) ⁽²⁾	55.5	59.3
Shares Outstanding (Mn)	30.5	
-12m (Max/Med/Min EUR)	2.42 / 1.98 / 1.68	
Daily Avg volume (-12m Mn EUR)	0.03	
Rotation ⁽³⁾	15.5	
Factset / Bloomberg	PANG-ES / PANG SM	
Close fiscal year	31-Dec	

Shareholders Structure (%) ⁽⁷⁾

GPI (Domínguez Family, Mayoral)	13.8
Vidaro Inv. (Villagrà Blanco Fam.)	8.2
Mirling Europe	6.6
Hersol XXI (Solans Family)	4.4
Free Float	12.4

Financials (Mn EUR)

	2023	2024e	2025e	2026e
Adj. nº shares (Mn)	27.1	30.5	30.5	30.5
Total Revenues	8.0	13.8	14.8	15.7
Rec. EBITDA	-3.0	-1.1	-0.3	0.2
% growth	9.5	64.3	74.5	181.2
% Rec. EBITDA/Rev.	n.a.	n.a.	n.a.	1.4
% Inc. EBITDA sector ⁽⁴⁾	-21.5	26.1	27.4	25.4
Net Profit	-4.7	-1.5	-0.7	-0.1
EPS (EUR)	-0.17	-0.05	-0.02	0.00
% growth	-44.7	70.6	54.1	81.5
Ord. EPS (EUR)	-0.11	-0.05	-0.03	-0.01
% growth	2.3	52.8	47.3	61.0
Rec. Free Cash Flow ⁽⁵⁾	-3.5	-2.2	-0.9	-0.3
Pay-out (%)	0.0	0.0	0.0	0.0
DPS (EUR)	0.00	0.00	0.00	0.00
Net financial debt	2.9	4.9	5.6	5.6
ND/Rec. EBITDA (x)	n.a.	n.a.	n.a.	25.2
ROE (%)	n.a.	n.a.	n.a.	n.a.
ROCE (%) ⁽⁵⁾	n.a.	n.a.	n.a.	0.6

Ratios & Multiples (x) ⁽⁶⁾

	n.a.	n.a.	n.a.	n.a.
P/E	n.a.	n.a.	n.a.	n.a.
Ord. P/E	n.a.	n.a.	n.a.	n.a.
P/BV	3.0	3.3	3.4	3.5
Dividend Yield (%)	0.0	0.0	0.0	0.0
EV/Sales	6.94	4.02	3.74	3.54
EV/Rec. EBITDA	n.a.	n.a.	n.a.	n.a.
EV/EBIT	n.a.	n.a.	n.a.	n.a.
FCF Yield (%) ⁽⁵⁾	n.a.	n.a.	n.a.	n.a.

(1) The opinion regarding the results is on reported EBITDA with respect to our estimate for the year (12m). The impact reflects whether, due to the results, we envisage a significant revision (>5% - 10%, depending on the sector) of our EBITDA estimate (for any of the estimated years).

(2) Please refer to Appendix 3.

(3) Rotation is the % of the capitalisation traded - 12m.

(4) Sector: Europe Biotechnology.

(5) Please see Appendix 2 for the theoretical tax rate (ROCE) and rec. FCF calculation.

(6) Multiples and ratios calculated over prices at the date of this report.

(7) Others: Founders 13.2%, Irigen 6.6%, Eléctrica del Oeste 6.3%, Areyhold S.L.U. 6.2%, Serpis 5.9%, Ideas de Bombero 5.8%, Orensanas 5.5%, Asfodel 5.1%.

(*) Unless otherwise indicated, all the information contained in this report is based on: The Company, Factset and Lighthouse.

FY23 earnings: sharp jump driven by M&A, but corporate services still held back EBITDA

M&A DROVE REVENUE GROWTH (EUR 8MN VS EUR 4.4MN IN 2022)... Revenue growth in 2023 was essentially the result of: i) the integration of IOB (pro forma revenue: EUR 8.2Mn), Pectus and IBCC, which combined accounted for c.85% of the total increase, and ii) organic growth, led by management of the pulmonology area of Hospital Universitario General de Cataluña, which contributed c. EUR 0.4Mn in 2023.

...BUT NOT AS MUCH AS WE HAD EXPECTED DUE TO THE CORPORATE SERVICES LINE (TOTAL REVENUE IN 2023: -25% VS OUR ESTIMATES). Revenue from corporate services (contracts with large pharmaceutical companies) was steady at EUR 0.9Mn (vs EUR 2.5Mn estimated). Revenue from this business line is only recognised when activity (number of patients) reaches a certain threshold each period. This held back earnings in 2023. However, the order backlog increased to EUR 4Mn in 2023 vs EUR 3.2Mn in 2022 which, with growth in new patients (as of 2024e), bodes well for improvement in this business line.

RECURRING EBITDA LOSS IN 2023 OF EUR 3MN (VS EUR -3.3MN IN 2022). The improvement in gross margin in 2023 to 72.5% (+31.2p.p., thanks primarily to IOB's integration) was not enough to make up for overhead, which held back recurring EBITDA, resulting in a loss of EUR 3Mn (vs EUR -1.3Mn expected).

DEBT REMAINED IN CHECK (ND/EQUITY 2023: 0.2X). Most of the M&A deals (total EV: EUR 5.4Mn) entailed the delivery of treasury shares held by PANG, which resulted in PANG ending the year with net debt of EUR 2.9Mn (net vs cash in 2022). This paves the way for the company to continue with its inorganic growth strategy.

WE ARE CUTTING OUR ESTIMATES. We are revising down our estimates in the wake of the (lower-than-expected) FY23 earnings. Our baseline scenario calls for revenue in 2024e of around EUR 13.8Mn (-15% vs our previous estimate) and a recurring EBITDA loss of EUR 1.1Mn (vs the positive EUR 1Mn previously estimated).

PANG'S EQUITY STORY NOW HINGES ON EXTRACTING SYNERGIES AND IMPROVING MARGINS. All eyes should not be on 2024e, with M&A fully integrated and the (more profitable) corporate services line set to take off. The crux of the equity story after 2023 earnings (and continuing over the long term) is margin expansion. We expect PANG to achieve break-even at EBITDA level in 2026e.

Relative performance (Base 100)


Stock performance (%)	-1m	-3m	-12m	YTD	-3Y	-5Y
Absolute	-5.9	-7.4	-3.8	-4.9	-22.8	-7.6
vs Ibxex 35	-5.0	-14.3	-19.7	-11.6	-37.4	-19.9
vs Ibxex Small Cap Index	-9.7	-12.9	-11.0	-9.6	-21.2	-23.7
vs Eurostoxx 50	-3.0	-11.9	-15.6	-12.1	-37.3	-34.1
vs Sector benchmark ⁽⁴⁾	-6.0	-14.5	-11.2	-10.3	30.3	-4.0

Pangaea Oncology (PANG) is a BME Growth company

BME Growth is the segment of BME MTF Equity aimed at small and medium sized companies, directed and managed by the Spanish stock market and is subject to the CNMV supervision. BME MTF Equity is not a Regulated Market but instead falls within the classification of a Multilateral Trading Facility (MTF) as defined under the Markets in Financial Instruments Directive (MiFID). In July 2020, BME Growth obtained the status of SME Growth Market, a new category of EU regulations, which in Spain is called Mercado de Pymes en Expansión.

BME Growth is the Spanish equity market for companies of reduced capitalization which aim to grow, with a special set of regulations, designed specifically for them, and with costs and process tailored to their particular features. Operations in BME Growth (former MAB) started in July 2009. There are currently c.140 companies listed on it. Companies listed on the MAB can choose to present their financial statements under IFRS or the General Accounting Plan (PGC) and Royal Decree 1159/2010 (NOFCAC).

12m Results 2023
Estimates downgrade
Table 1. 2023 Results

	12m23 Real	12m22	12m23 Real vs 12m22	2023e	2023 vs 2023e
Total Revenues	8.0	4.4	83.1%	10.8	-25.9%
Medical services	7.1	3.3	111.4%	8.3	-14.5%
Corporate Services (DX)	0.9	1.0	-9.3%	2.5	-63.3%
Gross Margin	5.8	1.8	221.3%	6.3	-7.8%
<i>Gross Margin/Revenues</i>	<i>72.5%</i>	<i>41.3%</i>	<i>31.2 p.p.</i>	<i>77.9%</i>	<i>36.6 p.p.</i>
Recurrent EBITDA⁽¹⁾	-3.0	-3.3	9.5%	-1.1	-180.0%
<i>Rec. EBITDA/Revenues</i>	<i>-37.7%</i>	<i>-76.2%</i>	<i>38.5 p.p.</i>	<i>-10.0%</i>	<i>66.3 p.p.</i>
EBITDA⁽²⁾	-3.5	-3.6	4.8%	-0.8	-311.0%
<i>EBITDA/Revenues</i>	<i>-43.2%</i>	<i>-83.0%</i>	<i>39.9 p.p.</i>	<i>-7.8%</i>	<i>75.2 p.p.</i>
EBIT	-3.8	-2.6	-49.3%	-1.2	-218.2%
PBT	-3.5	-2.8	-23.5%	-1.5	-140.1%
NP	-4.7	-2.7	-71.7%	-1.5	-201.8%
Ordinary NP	-4.1	-2.4	-67.2%	-1.6	-160.1%
<i>New patients</i>	<i>3,116</i>	<i>1,608</i>	<i>93.8%</i>		
<i>Total visits</i>	<i>40,743</i>	<i>28,542</i>	<i>42.7%</i>		
<i>Clinical trials</i>	<i>364</i>	<i>206</i>	<i>76.7%</i>		
<i>Surgical activities</i>	<i>235</i>	<i>212</i>	<i>10.8%</i>		
<i>Pharma clients</i>	<i>77</i>	<i>67</i>	<i>14.9%</i>		
Net Debt/Net Cash	2.9	-4.8	162%	1.3	126.1%

(1) Note 1: Rec. EBITDA does not include subsidies or capitalised expenses or M&A related expenses.

(2) Note 2: EBITDA does not include capitalised expenses


Net debt includes earn-outs from M&A operations

Table 2. Estimates downgrade


EUR Mn	2024e (New)	2024e	Review (%)	2025e (New)	2025e	Review (%)	2026e (New)
Total Revenues	13.8	16.2	-15.0%	14.8	17.8	-16.5%	15.7
Recurrent EBITDA	-1.1	1.0	-209.0%	-0.3	1.8	-115.6%	0.2
<i>Rec. EBITDA/Revenues</i>	<i>n.a.</i>	<i>6.1%</i>	<i>n.a.</i>	<i>n.a.</i>	<i>9.9%</i>	<i>n.a.</i>	<i>1.4%</i>
EBIT	-1.2	1.3	-194.9%	-0.4	1.9	-119.8%	0.1
Net Profit	-1.6	0.7	-324.7%	-0.7	1.4	-151.7%	-0.2
Recurrent Free Cash Flow	-2.8	-0.8	-262.0%	-1.6	-0.1	-1057.6%	-0.4
<i>Net Debt/(Net Cash)</i>	<i>5.5</i>	<i>1.9</i>	<i>193%</i>	<i>6.8</i>	<i>1.8</i>	<i>280%</i>	<i>6.9</i>

The company in 8 charts


PANG is committed to a technology (liquid biopsy) with rational expectations for high growth ...




... and is faced with a genuine step up in scale (+25.1% CAGR 23-26e)




The M&A already executed in 2023e will explain c. 91% of total growth for the year 2024e




The improvement of margins is the business' main catalyst (gross margin c. 79% from 2024e)




The combination of growth and improved margins points to breakeven in EBITDA in 2026e...




... and will make it possible to reduce cash consumption (breakeven) as early as 2025e



With a strong balance sheet structure (net cash) that will allow it to finance inorganic growth without capital increase



The high volume of activity will increase the speed of expansion of molecular diagnostics (liquid biopsy) in the long term



Valuation inputs

Inputs for the DCF Valuation Approach

	2024e	2025e	2026e	Terminal Value ⁽¹⁾		
Free Cash Flow "To the Firm"	(2.2)	(0.9)	(0.3)	n.a.		
Market Cap	53.4	At the date of this report				
Net financial debt	2.9	Debt net of Cash (12m Results 2023)				
					Best Case	Worst Case
Cost of Debt	5.0%	Net debt cost			4.8%	5.3%
Tax rate (T)	20.0%	T (Normalised tax rate)			=	=
Net debt cost	4.0%	Kd = Cost of Net Debt * (1-T)			3.8%	4.2%
Risk free rate (rf)	3.3%	Rf (10y Spanish bond yield)			=	=
Equity risk premium	6.0%	R (own estimate)			5.5%	6.5%
Beta (B)	1.3	B (own estimate)			1.2	1.4
Cost of Equity	11.1%	Ke = Rf + (R * B)			9.9%	12.4%
Equity / (Equity + Net Debt)	94.8%	E (Market Cap as equity value)			=	=
Net Debt / (Equity + Net Debt)	5.2%	D			=	=
WACC	10.8%	WACC = Kd * D + Ke * E			9.6%	12.0%
G "Fair"	2.0%				2.5%	1.5%

(1) The terminal value calculated beyond the last FCF estimate does not reflect the company's growth potential (positive/negative) at the date of publication of this report.

Inputs for the Multiples Valuation Approach

Company	Ticker Factset	Mkt. Cap	P/E 24e	EPS 24e-26e	EV/EBITDA 24e	EBITDA 24e-26e	EV/Sales 24e	Revenues 24e-26e	EBITDA/Sales 24e	FCF Yield 24e	FCF 24e-26e
MDxHealth SA	MDXH-BE	75.8	n.a.	38.3%	n.a.	59.5%	1.3	15.0%	n.a.	n.a.	43.2%
Biocartis	BCART-BE	27.2	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Atrys Health	ATRY-ES	219.7	46.0	n.a.	9.7	17.7%	1.9	7.6%	20.0%	6.4%	2.9%
Guardant Health Inc	GH-US	2,118.8	n.a.	8.0%	n.a.	14.0%	3.7	22.5%	n.a.	n.a.	11.1%
Exact Sciences Corp	EXAS-US	10,413.3	n.a.	73.9%	39.1	38.0%	4.6	13.6%	11.7%	1.3%	93.2%
Neogenomics Inc.	NEO-US	1,758.8	n.a.	n.a.	n.a.	79.9%	3.2	9.7%	3.5%	n.a.	n.a.
Molecular Diagnostic Laboratories			46.0	40.0%	24.4	41.8%	2.9	13.7%	11.7%	3.9%	37.6%
Thermo Fisher	TMO-US	204,008.1	26.3	11.9%	22.8	9.8%	5.7	7.3%	25.2%	3.3%	12.2%
Qiagen	QGEN-US	8,838.9	20.3	9.5%	14.3	9.4%	5.0	6.7%	35.1%	5.3%	4.4%
Danaher	DHR-US	171,054.0	32.5	12.6%	25.4	10.3%	8.2	8.3%	32.2%	3.3%	9.2%
Agilent	A-US	37,705.0	25.0	10.2%	20.6	8.9%	6.1	6.6%	29.6%	3.3%	14.4%
Becton Dickinson	BDX-US	64,964.8	18.5	9.6%	14.1	8.9%	4.2	5.7%	29.5%	4.3%	19.4%
Advanced Medical Equipment			24.5	10.8%	19.4	9.5%	5.8	6.9%	30.3%	3.9%	11.9%
Roche	ROG-CH	179,646.3	11.8	8.1%	8.6	6.4%	3.2	5.1%	37.5%	7.7%	6.7%
PANG	PANG-ES	53.4	n.a.	70.9%	n.a.	59.2%	4.0	6.5%	n.a.	n.a.	83.8%


Appendix 1. Financial Projections

Balance Sheet (EUR Mn)	2019	2020	2021	2022	2023	2024e	2025e	2026e	CAGR	
Intangible assets	7.1	7.0	8.2	9.6	12.7	12.4	12.3	12.1		
Fixed assets	0.6	0.6	0.4	0.4	0.5	0.5	0.5	0.5		
Other Non Current Assets	4.0	3.9	4.0	4.0	2.7	2.2	1.8	1.5		
Financial Investments	0.0	0.0	0.6	0.5	0.1	(0.0)	(0.1)	(0.2)		
Goodwill & Other Intangibles	0.0	0.0	0.0	0.6	3.2	3.2	3.2	3.2		
Current assets	3.6	4.3	4.6	4.8	6.8	10.5	11.4	11.9		
Total assets	15.4	15.8	17.9	19.9	26.0	28.9	29.1	29.0		
Equity	8.3	8.3	14.1	22.9	17.8	16.3	15.6	15.4		
Minority Interests	-	-	-	0.2	1.0	0.8	0.7	0.6		
Provisions & Other L/T Liabilities	0.3	0.2	0.3	0.3	1.0	1.0	1.0	1.0		
Other Non Current Liabilities	-	-	-	-	-	-	-	-		
Net financial debt	5.5	5.7	2.4	(4.8)	2.9	4.9	5.6	5.6		
Current Liabilities	1.3	1.5	1.1	1.3	3.2	5.9	6.3	6.4		
Equity & Total Liabilities	15.4	15.8	17.9	19.9	26.0	28.9	29.1	29.0		
P&L (EUR Mn)	2019	2020	2021	2022	2023	2024e	2025e	2026e	19-23	23-26e
Total Revenues	3.3	4.1	4.6	4.4	8.0	13.8	14.8	15.7	24.6%	25.1%
<i>Total Revenues growth</i>	<i>8.4%</i>	<i>23.6%</i>	<i>12.3%</i>	<i>-5.1%</i>	<i>83.1%</i>	<i>72.5%</i>	<i>7.6%</i>	<i>5.5%</i>		
COGS	(1.1)	(1.6)	(1.5)	(2.6)	(2.2)	(3.0)	(3.2)	(3.3)		
Gross Margin	2.2	2.5	3.1	1.8	5.8	10.8	11.7	12.3	27.1%	28.6%
<i>Gross Margin/Revenues</i>	<i>66.9%</i>	<i>61.9%</i>	<i>66.6%</i>	<i>41.3%</i>	<i>72.5%</i>	<i>77.9%</i>	<i>78.8%</i>	<i>78.8%</i>		
Personnel Expenses	(2.7)	(2.8)	(3.2)	(3.6)	(5.6)	(8.0)	(8.1)	(8.2)		
Other Operating Expenses	(1.3)	(1.2)	(1.5)	(1.5)	(3.2)	(3.8)	(3.9)	(3.9)		
Recurrent EBITDA	(1.7)	(1.5)	(1.6)	(3.3)	(3.0)	(1.1)	(0.3)	0.2	-14.7%	27.5%
<i>Recurrent EBITDA growth</i>	<i>25.3%</i>	<i>11.7%</i>	<i>-2.8%</i>	<i>-110.5%</i>	<i>9.5%</i>	<i>64.3%</i>	<i>74.5%</i>	<i>181.2%</i>		
<i>Rec. EBITDA/Revenues</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>1.4%</i>		
Restructuring Expense & Other non-rec.	0.3	0.2	(0.1)	(0.3)	(0.4)	0.2	0.2	0.2		
EBITDA	(1.4)	(1.3)	(1.6)	(3.6)	(3.5)	(0.8)	(0.0)	0.4	-25.2%	28.7%
Depreciation & Provisions	(3.1)	(2.4)	(1.0)	(1.2)	(2.3)	(2.2)	(2.2)	(2.2)		
Capitalized Expense	2.2	2.1	2.1	2.3	2.0	1.9	1.9	1.9		
Rentals (IFRS 16 impact)	-	-	-	-	-	-	-	-		
EBIT	(2.3)	(1.6)	(0.5)	(2.6)	(3.8)	(1.2)	(0.4)	0.1	-13.6%	26.8%
<i>EBIT growth</i>	<i>-26.7%</i>	<i>29.3%</i>	<i>67.1%</i>	<i>-380.1%</i>	<i>-49.3%</i>	<i>68.6%</i>	<i>68.7%</i>	<i>139.5%</i>		
<i>EBIT/Revenues</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>0.9%</i>		
Impact of Goodwill & Others	(2.5)	-	-	-	-	-	-	-		
Net Financial Result	(0.2)	(0.2)	(0.4)	(0.1)	0.4	(0.2)	(0.2)	(0.3)		
Income by the Equity Method	-	(0.0)	(0.2)	(0.2)	(0.1)	(0.1)	(0.1)	(0.1)		
Ordinary Profit	(5.0)	(1.9)	(1.1)	(2.8)	(3.5)	(1.5)	(0.7)	(0.2)	8.4%	59.5%
<i>Ordinary Profit Growth</i>	<i>-134.2%</i>	<i>62.6%</i>	<i>41.1%</i>	<i>-158.5%</i>	<i>-23.5%</i>	<i>58.3%</i>	<i>49.7%</i>	<i>68.3%</i>		
Extraordinary Results	-	-	-	-	-	-	-	-		
Profit Before Tax	(5.0)	(1.9)	(1.1)	(2.8)	(3.5)	(1.5)	(0.7)	(0.2)	8.4%	59.5%
Tax Expense	0.1	0.1	0.5	0.1	(1.3)	(0.2)	(0.1)	(0.0)		
<i>Effective Tax Rate</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>	<i>n.a.</i>		
Minority Interests	-	-	-	0.0	0.1	0.1	0.1	0.1		
Discontinued Activities	-	-	-	-	-	-	-	-		
Net Profit	(4.8)	(1.8)	(0.6)	(2.7)	(4.7)	(1.5)	(0.7)	(0.1)	1.0%	69.6%
<i>Net Profit growth</i>	<i>-286.4%</i>	<i>63.8%</i>	<i>63.4%</i>	<i>-322.5%</i>	<i>-71.7%</i>	<i>66.9%</i>	<i>54.1%</i>	<i>81.5%</i>		
Ordinary Net Profit	(5.3)	(2.1)	(1.0)	(2.5)	(2.9)	(1.6)	(0.8)	(0.3)	13.9%	52.2%
<i>Ordinary Net Profit growth</i>	<i>-123.7%</i>	<i>60.3%</i>	<i>51.1%</i>	<i>-144.6%</i>	<i>-15.9%</i>	<i>46.8%</i>	<i>47.3%</i>	<i>61.0%</i>		
Cash Flow (EUR Mn)	2019	2020	2021	2022	2023	2024e	2025e	2026e	19-23	23-26e
Recurrent EBITDA						(1.1)	(0.3)	0.2	-14.7%	27.5%
Rentals (IFRS 16 impact)						-	-	-		
Working Capital Increase						(1.0)	(0.5)	(0.4)		
Recurrent Operating Cash Flow						-2.1	-0.8	-0.1	-10.1%	64.5%
CAPEX						(0.1)	(0.1)	(0.2)		
Net Financial Result affecting the Cash Flow						(0.2)	(0.2)	(0.3)		
Tax Expense						0.3	0.3	0.3		
Recurrent Free Cash Flow						(2.2)	(0.9)	(0.3)	-16.6%	56.9%
Restructuring Expense & Other non-rec.						0.2	0.2	0.2		
- Acquisitions / + Divestures of assets						-	-	-		
Extraordinary Inc./Exp. Affecting Cash Flow						-	-	-		
Free Cash Flow						(2.0)	(0.7)	(0.1)	-34.3%	78.8%
Capital Increase						-	-	-		
Dividends						-	-	-		
Net Debt Variation						2.0	0.7	0.1		


Appendix 2. Free Cash Flow

A) Cash Flow Analysis (EUR Mn)	2020	2021	2022	2023	2024e	2025e	2026e	CAGR	
								20-23	23-26e
Recurrent EBITDA	(1.5)	(1.6)	(3.3)	(3.0)	(1.1)	(0.3)	0.2	-25.1%	27.5%
<i>Recurrent EBITDA growth</i>	11.7%	-2.8%	-110.5%	9.5%	64.3%	74.5%	181.2%		
<i>Rec. EBITDA/Revenues</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1.4%		
- Rentals (IFRS 16 impact)	-	-	-	-	-	-	-		
+/- Working Capital increase	(0.5)	(0.7)	(0.0)	(0.1)	(1.0)	(0.5)	(0.4)		
= Recurrent Operating Cash Flow	(2.0)	(2.3)	(3.4)	(3.1)	(2.1)	(0.8)	(0.1)	-14.9%	64.5%
<i>Rec. Operating Cash Flow growth</i>	3.2%	-11.0%	-49.7%	8.7%	31.8%	61.9%	82.8%		
<i>Rec. Operating Cash Flow / Sales</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
- CAPEX	(0.1)	(0.3)	(0.0)	(0.3)	(0.1)	(0.1)	(0.2)		
- Net Financial Result affecting Cash Flow	(0.2)	(0.4)	(0.1)	(0.0)	(0.2)	(0.2)	(0.3)		
- Taxes	0.3	0.7	0.1	(0.1)	0.3	0.3	0.3		
= Recurrent Free Cash Flow	(2.0)	(2.2)	(3.4)	(3.5)	(2.2)	(0.9)	(0.3)	-20.0%	56.9%
<i>Rec. Free Cash Flow growth</i>	-6.9%	-10.0%	-56.4%	-0.5%	36.7%	58.7%	69.4%		
<i>Rec. Free Cash Flow / Revenues</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
- Restructuring expenses & others	(0.0)	0.1	(0.3)	(0.4)	0.2	0.2	0.2		
- Acquisitions / + Divestments	(0.3)	(0.2)	(0.1)	(1.5)	-	-	-		
+/- Extraordinary Inc./Exp. affecting Cash Flow	-	-	-	-	-	-	-		
= Free Cash Flow	(2.3)	(2.4)	(3.9)	(5.4)	(2.0)	(0.7)	(0.1)	-32.0%	78.8%
<i>Free Cash Flow growth</i>	-41.1%	-0.8%	-63.3%	-39.9%	63.8%	65.3%	92.4%		
<i>Recurrent Free Cash Flow - Yield (s/Mkt Cap)</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<i>Free Cash Flow Yield (s/Mkt Cap)</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
B) Analytical Review of Annual Recurrent Free Cash Flow Performance (Eur Mn)									
	2020	2021	2022	2023	2024e	2025e	2026e	CAGR	
Recurrent FCF(FY - 1)	(1.9)	(2.0)	(2.2)	(3.4)	(3.5)	(2.2)	(0.9)		
EBITDA impact from revenue increase	(0.4)	(0.2)	0.1	(2.8)	(2.2)	(0.1)	(0.0)		
EBITDA impact from EBITDA/Sales variation	0.6	0.1	(1.8)	3.1	4.1	0.9	0.5		
= Recurrent EBITDA variation	0.2	(0.0)	(1.7)	0.3	1.9	0.8	0.5		
- Rentals (IFRS 16 impact) variation impact	-	-	-	-	-	-	-		
+/- Working capital variation impact	(0.1)	(0.2)	0.6	(0.0)	(1.0)	0.5	0.2		
= Recurrent Operating Cash Flow variation	0.1	(0.2)	(1.1)	0.3	1.0	1.3	0.7		
+/- CAPEX impact	(0.1)	(0.3)	0.3	(0.2)	0.1	(0.0)	(0.0)		
+/- Financial result variation	(0.0)	(0.2)	0.2	0.1	(0.2)	(0.0)	(0.0)		
+/- Tax impact	(0.1)	0.4	(0.7)	(0.2)	0.4	0.0	(0.0)		
= Recurrent Free Cash Flow variation	(0.1)	(0.2)	(1.2)	(0.0)	1.3	1.3	0.6		
Recurrent Free Cash Flow	(2.0)	(2.2)	(3.4)	(3.5)	(2.2)	(0.9)	(0.3)		
C) "FCF to the Firm" (pre debt service) (EUR Mn)									
	2020	2021	2022	2023	2024e	2025e	2026e	CAGR	
EBIT	(1.6)	(0.5)	(2.6)	(3.8)	(1.2)	(0.4)	0.1	-33.0%	26.8%
* Theoretical Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
= Taxes (pre- Net Financial Result)	-	-	-	-	-	-	-		
Recurrent EBITDA	(1.5)	(1.6)	(3.3)	(3.0)	(1.1)	(0.3)	0.2	-25.1%	27.5%
- Rentals (IFRS 16 impact)	-	-	-	-	-	-	-		
+/- Working Capital increase	(0.5)	(0.7)	(0.0)	(0.1)	(1.0)	(0.5)	(0.4)		
= Recurrent Operating Cash Flow	(2.0)	(2.3)	(3.4)	(3.1)	(2.1)	(0.8)	(0.1)	-14.9%	64.5%
- CAPEX	(0.1)	(0.3)	(0.0)	(0.3)	(0.1)	(0.1)	(0.2)		
- Taxes (pre- Financial Result)	-	-	-	-	-	-	-		
= Recurrent Free Cash Flow (To the Firm)	(2.1)	(2.6)	(3.4)	(3.3)	(2.2)	(0.9)	(0.3)	-16.6%	55.5%
<i>Rec. Free Cash Flow (To the Firm) growth</i>	-0.2%	-22.5%	-31.8%	1.7%	32.9%	57.6%	68.9%		
<i>Rec. Free Cash Flow (To the Firm) / Revenues</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
- Acquisitions / + Divestments	(0.3)	(0.2)	(0.1)	(1.5)	-	-	-		
+/- Extraordinary Inc./Exp. affecting Cash Flow	-	-	-	-	-	-	-		
= Free Cash Flow "To the Firm"	(2.4)	(2.8)	(3.5)	(4.8)	(2.2)	(0.9)	(0.3)	-25.8%	60.7%
<i>Free Cash Flow (To the Firm) growth</i>	-15.8%	-16.1%	-24.6%	-37.7%	53.7%	57.6%	68.9%		
<i>Rec. Free Cash Flow To the Firm Yield (o/EV)</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
<i>Free Cash Flow "To the Firm" - Yield (o/EV)</i>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		


Recurrent Free Cash Flow accumulated variation analysis (2019 - 2023)



Recurrent Free Cash Flow accumulated variation analysis (2023 - 2026e)



Recurrent EBITDA vs Recurrent Free Cash Flow



Stock performance vs EBITDA 12m forward



Appendix 3. EV breakdown at the date of this report

	EUR Mn	Source
Market Cap	53.4	
+ Minority Interests	1.0	12m Results 2023
+ Provisions & Other L/T Liabilities	1.0	12m Results 2023
+ Net financial debt	2.9	12m Results 2023
- Financial Investments	0.1	12m Results 2023
+/- Others ⁽¹⁾	(2.7)	12m Results 2023
Enterprise Value (EV)	55.5	

(1) Tax loss carry forward

Appendix 4. Historical performance ⁽¹⁾

Historical performance (EUR Mn)														CAGR		
	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	15-23	23-26e
Total Revenues	3.1	1.7	1.9	2.5	2.6	3.1	3.3	4.1	4.6	4.4	8.0	13.8	14.8	15.7	19.3%	25.1%
Total Revenues growth	17.7%	-44.4%	13.5%	29.1%	4.1%	16.7%	8.4%	23.6%	12.3%	-5.1%	83.1%	72.5%	7.6%	5.5%		
EBITDA	(0.5)	(1.6)	(2.0)	(3.3)	(4.5)	(2.1)	(1.4)	(1.3)	(1.6)	(3.6)	(3.5)	(0.8)	(0.0)	0.4	-7.4%	28.7%
EBITDA growth	61.2%	-237.0%	-22.1%	-69.4%	-37.0%	54.0%	32.7%	8.1%	-27.6%	-120.3%	4.8%	75.7%	94.1%	n.a.		
EBITDA/Sales	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	2.9%		
Net Profit	0.1	(0.2)	(0.5)	(0.6)	(1.6)	(1.3)	(4.8)	(1.8)	(0.6)	(2.7)	(4.7)	(1.5)	(0.7)	(0.1)	#####	69.6%
Net Profit growth	124.9%	-289.1%	-147.7%	-22.2%	-177.0%	23.9%	-286.4%	63.8%	63.4%	-322.5%	-71.7%	66.9%	54.1%	81.5%		
Adjusted number shares (Mn)	0.2	0.2	0.2	0.2	11.9	11.9	14.5	17.1	18.9	22.8	27.1	30.5	30.5	30.5		
EPS (EUR)	0.63	-1.20	-2.63	-3.23	-0.14	-0.10	-0.33	-0.10	-0.03	-0.12	-0.17	-0.05	-0.02	0.00	28.9%	70.8%
EPS growth	n.a.	n.a.	n.a.	-23.0%	95.7%	23.9%	n.a.	69.3%	66.8%	n.a.	-44.7%	70.6%	54.1%	81.5%		
Ord. EPS (EUR)	0.57	-1.28	-2.91	-3.27	-0.14	-0.12	-0.37	-0.12	-0.05	-0.11	-0.11	-0.05	-0.03	-0.01	33.7%	54.0%
Ord. EPS growth	n.a.	n.a.	n.a.	-12.3%	95.9%	13.2%	n.a.	66.3%	55.6%	n.a.	2.3%	52.8%	47.3%	61.0%		
CAPEX	(0.1)	(0.1)	(0.2)	(0.5)	(0.2)	(0.0)	(0.0)	(0.1)	(0.3)	(0.0)	(0.3)	(0.1)	(0.1)	(0.2)		
CAPEX/Sales %	3.5%	3.5%	12.0%	21.8%	5.9%	0.9%	0.0%	1.7%	7.0%	0.5%	3.2%	1.0%	1.0%	1.0%		
Free Cash Flow	(0.7)	(1.9)	(2.8)	(2.8)	(5.8)	(2.7)	(1.7)	(2.3)	(2.4)	(3.9)	(5.4)	(2.0)	(0.7)	(0.1)	-8.6%	78.8%
ND/EBITDA (x) ⁽²⁾	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	12.5x		
P/E (x)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
EV/Sales (x)	1.19x	3.26x	4.30x	1.92x	16.34x	10.84x	10.50x	8.45x	6.33x	6.99x	6.86x	4.02x	3.74x	3.54x		
EV/EBITDA (x) ⁽²⁾	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.		
Absolute performance	n.a.	n.a.	n.a.	n.a.	-22.0%	-3.8%	-16.3%	-5.9%	-1.9%	6.0%	12.2%	-4.9%				
Relative performance vs Ibx35	n.a.	n.a.	n.a.	n.a.	-27.4%	13.2%	-25.2%	11.3%	-9.1%	12.2%	-8.6%	-11.6%				

Note 1: The multiples are historical, calculated based on the price and EV at the end of each year, except (if applicable) in the current year, when multiples would be given at current prices. The absolute and relative behavior corresponds to each exercise (1/1 to 31/12). The source, both historical multiples and the evolution of the price, is Factsset.

Note 2: All ratios and multiples on EBITDA refer to total EBITDA (not to recurrent EBITDA).

Appendix 5. Main peers 2024e

	Molecular Diagnostic Laboratories							Advanced Medical Equipment					Global Leader			
	EUR Mn	MDxHealth SA	Biocartis	Atrys Health	Guardant Health Inc	Exact Sciences Corp	Neogenomics Inc.	Average	Thermo Fisher	Qigen	Danaher	Agilent	Becton Dickinson	Average	Roche	PANG
Market data																
Ticker (Factset)		MDXH-BE	BCART-BE	ATRY-ES	GH-US	EXAS-US	NEO-US		TMO-US	QGEN-US	DHR-US	A-US	BDX-US		ROG-CH	PANG-ES
Country		Belgium	Belgium	Spain	USA	USA	USA		USA	Netherlands	USA	USA	USA		Switzerland	Spain
Market cap		75.8	27.2	219.7	2,118.8	10,413.3	1,758.8		204,008.1	8,838.9	171,054.0	37,705.0	64,964.8		179,646.3	53.4
Enterprise value (EV)		100.5	154.3	431.6	2,292.0	12,087.1	1,967.8		230,650.8	9,409.9	182,502.9	38,613.4	78,940.6		199,621.7	55.5
Basic financial information																
Total Revenues		78.6	n.a.	223.0	621.1	2,649.3	613.4		40,204.5	1,878.4	22,311.1	6,327.4	18,945.7		62,021.4	13.8
Total Revenues growth		21.1%	n.a.	10.6%	17.7%	13.3%	10.8%	14.7%	0.3%	2.2%	-0.2%	-1.0%	4.5%		3.1%	72.5%
2y CAGR (24e - 26e)		15.0%	n.a.	7.6%	22.5%	13.6%	9.7%	13.7%	7.3%	6.7%	8.3%	6.6%	5.7%		5.1%	6.5%
EBITDA		(11.7)	n.a.	44.6	(308.9)	308.8	21.7		10,125.0	659.1	7,174.6	1,874.3	5,594.2		23,259.5	(0.8)
EBITDA growth		36.7%	n.a.	33.1%	36.5%	532.2%	196.3%	167.0%	-0.3%	8.3%	3.0%	5.5%	37.2%		10.7%	75.7%
2y CAGR (24e - 26e)		59.5%	n.a.	17.7%	14.0%	38.0%	79.9%	41.8%	9.8%	9.4%	10.3%	8.9%	8.9%		9.5%	59.2%
EBITDA/Revenues		n.a.	n.a.	20.0%	n.a.	11.7%	3.5%	11.7%	25.2%	35.1%	32.2%	29.6%	29.5%		30.3%	n.a.
EBIT		(18.4)	n.a.	18.4	(408.5)	(120.9)	(81.9)		9,106.6	522.8	6,540.2	1,726.2	4,563.4		20,579.0	(1.2)
EBIT growth		26.1%	n.a.	384.2%	22.4%	58.4%	9.4%	100.1%	30.7%	25.5%	32.4%	13.3%	122.1%		44.8%	68.6%
2y CAGR (24e - 26e)		85.9%	n.a.	43.5%	9.0%	83.7%	30.5%	50.5%	9.8%	9.3%	11.8%	8.9%	8.7%		9.7%	45.7%
EBIT/Revenues		n.a.	n.a.	8.2%	n.a.	n.a.	n.a.	8.2%	22.7%	27.8%	29.3%	27.3%	24.1%		26.2%	33.2%
Net Profit		(26.1)	n.a.	(0.0)	(372.3)	(150.7)	(66.4)		7,789.1	443.3	5,345.5	1,509.6	3,541.1		14,033.6	(1.5)
Net Profit growth		34.5%	n.a.	99.9%	17.0%	21.1%	19.3%	38.4%	38.9%	38.8%	35.4%	30.1%	147.4%		58.1%	66.9%
2y CAGR (24e - 26e)		38.0%	n.a.	n.a.	7.8%	75.5%	34.2%	38.9%	10.4%	8.9%	12.5%	8.9%	9.8%		10.1%	70.9%
CAPEX/Sales %		6.7%	n.a.	5.7%	6.7%	5.2%	3.8%	5.6%	3.5%	8.0%	4.8%	5.8%	4.4%		5.3%	-1.0%
Free Cash Flow		(16.7)	n.a.	14.2	(318.0)	133.6	n.a.		6,763.2	468.3	5,586.8	1,255.7	2,801.5		13,876.3	(2.0)
Net financial debt		103.2	n.a.	159.4	125.0	1,402.4	248.1		21,778.5	303.1	7,669.1	524.9	11,732.9		14,350.9	4.9
ND/EBITDA (x)		n.a.	n.a.	3.6	n.a.	4.5	11.4	6.5	2.2	0.5	1.1	0.3	2.1		1.2	n.a.
Pay-out		0.0%	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	7.0%	0.0%	12.4%	17.2%	28.3%		13.0%	57.3%
Multiples and Ratios																
P/E (x)		n.a.	n.a.	46.0	n.a.	n.a.	n.a.	46.0	26.3	20.3	32.5	25.0	18.5		24.5	11.8
P/BV (x)		n.a.	n.a.	0.7	n.a.	3.4	2.1	2.1	4.5	2.4	3.2	5.9	2.6		3.7	4.8
EV/Revenues (x)		1.3	n.a.	1.9	3.7	4.6	3.2	2.9	5.7	5.0	8.2	6.1	4.2		5.8	3.2
EV/EBITDA (x)		n.a.	n.a.	9.7	n.a.	39.1	n.a.	24.4	22.8	14.3	25.4	20.6	14.1		19.4	8.6
EV/EBIT (x)		n.a.	n.a.	23.5	n.a.	n.a.	n.a.	23.5	25.3	18.0	27.9	22.4	17.3		22.2	9.7
ROE		n.a.	n.a.	1.5	n.a.	n.a.	0.3	0.9	17.0	11.7	9.9	23.7	14.3		15.3	40.9
FCF Yield (%)		n.a.	n.a.	6.4	n.a.	1.3	n.a.	3.9	3.3	5.3	3.3	3.3	4.3		3.9	7.7
DPS		0.00	n.a.	0.00	0.00	0.00	0.00	0.00	1.41	0.00	0.90	0.88	3.50		1.34	10.06
Dvd Yield		n.a.	n.a.	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	0.0%	0.4%	0.7%	1.6%		0.6%	4.6%

Note 1: Financial data, multiples and ratios based on market consensus (Factset). In the case of the company analyzed, own estimates (Lighthouse).

Note 2: All ratios and multiples on EBITDA refer to total EBITDA (not to recurrent EBITDA).

LIGHTHOUSE

Calle Núñez de Balboa, 108 1ª Planta
28006 Madrid
T: +34 915 904 226
institodeanalistas.com/lighthouse

Alfredo Echevarría Otegui

Head of research

alfredo.echevarria@institodeanalistas.com

Luis Esteban Arribas, CESGA

Equity research

luis.esteban@institodeanalistas.com

Enrique Andrés Abad, CFA

Equity research

enrique.andres@institodeanalistas.com

José Miguel Cabrera van Grieken

Equity research

jose.cabrera@institodeanalistas.com

Jesús López Gómez, CESGA

ESG Analyst & Data analytics

jesus.lopez@institodeanalistas.com

All Lighthouse research documents are available simultaneously on the Lighthouse website (institodeanalistas.com/lighthouse) and via third-party aggregators such as Bloomberg, Factset, Capital IQ and Refinitiv.

IMPORTANT LEGAL INFORMATION REGARDING THIS REPORT

LIGHTHOUSE

Lighthouse is a project of IEF Servicios de Análisis S.L.U. Lighthouse is a research project funded by Bolsas y Mercados Españoles S.A. Lighthouse aims to improve the research coverage of the "orphan stocks" of the Spanish market: those which lack real and continuous research coverage. Lighthouse reports will not include valuation and target price. Lighthouse does not seek to provide investment advice to any natural or legal person. For this reason, Lighthouse will not provide a valuation, target price or investment recommendation for any of the securities analysed.

IEAF Servicios de Análisis S.L.U. is a Spanish company whose corporate purpose is:

- 1) To provide information and financial analysis regarding securities issued by any class of legal person traded or not on official secondary markets, and especially (but not exclusively) those securities which are not the object of the recurrent provision of information and analysis by financial analysts who participate in the markets.
- 2) To publicise and update the aforementioned financial reports and analysis, in addition to the monitoring and following of the securities on which the information and analysis is provided.
- 3) To prepare studies and projects aimed at proposing and implementing measures to improve the information and financial analysis of securities traded on official secondary markets.

IEAF Servicios de Análisis S.L.U. is a company whose sole shareholder is the Instituto Español de Analistas Financieros, a professional, not for profit association.

DISCLAIMER

The Instituto Español de Analistas Financieros hereby certifies that the analyst of IEF Servicios de Análisis S.L.U. whose name figures as the author of this report, expresses views that reflect their personal and independent opinion of the company analysed without these implying, either directly or indirectly, a personalised recommendation of the company analysed for purposes of providing investment advice. This report is based on the preparation of detailed financial projections from information available to the public and following traditional fundamental research methodology (i.e. it is not a technical or quantitative analysis report). For the analysis methodology used in the preparation of this report, please contact the analyst directly; contact details are included on the front page of this report.

The report includes basic information regarding the main parameters to be used by an investor when making their own valuation (whether by discounted cash flows or multiples). These parameters are the personal opinion or estimate of the analyst. The person receiving this report should use their own judgement when using these parameters and should consider them as another element in their decision-making process in respect of investment. These parameters do not represent a personalised investment recommendation.

Rules governing confidentiality and conflicts of interest

None of the following rules governing confidentiality and conflicts of interest (12) is applicable to this report:

1. This report is non-independent research as it has been commissioned by the company analysed (issuer).
2. In the last 12 months, the Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U., has had Investment Banking mandates or has managed or co-managed a public offering of the securities of the issuer, or has received compensation from said issuer for Investment Banking services, that exclude brokerage services for prepaid fees.
3. In the next 6 months, the Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U., expects to receive or intends to obtain compensation for Investment Banking services provided to this company that exclude brokerage services for prepaid fees.
4. The Investment Analyst or a member of the Research Department or a member of their household has a long position in the shares or derivatives of the corresponding issuer.
5. The Investment Analyst or a member of the Research Department or a member of their household has a short position in the shares or derivatives of the corresponding issuer.
6. At the date of publication, the Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U. held a long position of over 0.5% of the issuer's capital.
7. At the date of publication, the Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U. held a short position of over 0.5% of the issuer's capital.
8. At the end of the month immediately prior to the publication of this report, or of the previous month if the report is published in the ten days following the end of the month, the company analysed (the issuer) or any of its subsidiaries held 5% or more of any class of equity security of the Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U.
9. A senior director or officer of the Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U., or a member of their department is a director, officer, advisor or member of the Board of Directors of the issuer and/or one of its subsidiaries.
10. The Instituto Español de Analistas Financieros or its subsidiary, IEF Servicios de Análisis S.L.U., acts as broker for the Issuer for the corresponding prepaid fees.
11. The contents of this report related to the financial analysis, financial projections, valuation, investment summary and opinion of the analyst have been reviewed by the issuer prior to its publication.
12. The issuer has made changes to the contents of this report prior to its distribution.

The Investment Analysts who have prepared this Investment Analysis are employees of IEF Servicios de Análisis S.L.U. These analysts have received (or will receive) compensation according to the general earnings of IEF Servicios de Análisis S.L.U. To obtain a copy of the Code of Conduct of IEF Servicios de Análisis S.L.U. (in respect of the Management of Conflicts of Interest in the research department), please use the e-mail address secretaria@institutodeanalistas.com or consult the contents of this Code at <https://institutodeanalistas.com>.

IEAF Servicios de Análisis S.L.U. is compensated by Bolsas y Mercados Españoles, S.A. for the preparation of this report. This report should be considered as just another element in the taking of investment decisions.

A report issued by IEF servicios de análisis S.L.U.

All rights reserved. The unauthorised use or distribution of this report is prohibited. This document has been prepared and distributed, according to the provisions of the MiFID II by IEF Servicios de Análisis S.L.U. Its corporate activity is regulated by the CNMV (the Spanish Securities Exchange Commission). The information and opinions expressed in this document do not represent nor are they intended to represent an offer or a solicitation to buy or sell the securities (in other words, the securities mentioned in this report and related warrants, options, rights or interests). The information and opinions contained in this document are based upon information available to the public and have been obtained from sources believed to be reliable by IEF Servicios de Análisis S.L.U., but no guarantee is given regarding their accuracy or completeness. All comments and estimates reflect solely the opinion of IEF Servicios de Análisis S.L.U. and do not offer any implicit or explicit guarantee. All the opinions expressed are subject to change without prior warning. This document does not take into account the specific investment objectives, financial position, risk profile or other specific aspects of the person who receives this document, and accordingly they should exercise their own judgement in this respect. Neither the Instituto Español de Analistas Financieros nor its subsidiary, IEF Servicios de Análisis S.L.U., assumes any responsibility for direct or

indirect losses arising from the use of the published research, except in the event of negligent conduct by IEAF Servicios de Análisis S.L.U. The information contained in this report is approved for distribution to professional clients, eligible counterparties and professional advisers, but not for distribution to private individuals or retail clients. Its reproduction, distribution or publication for any purpose without the written authorisation of IEAF Servicios de Análisis S.L.U. is prohibited. The Instituto Español de Analistas Financieros and/or its subsidiary IEAF Servicios de Análisis S.L.U., their employees and directors, may hold a position (long or short) in an investment knowing that this issuer will be the object of analysis and that this analysis will be distributed to institutional investors. Any further information regarding the contents of this report will be provided upon request. IEAF Servicios de Análisis S.L.U. intends to publish (at least) one quarterly report or note updating the information on the company analysed.

United States. IEAF Servicios de Análisis S.L.U. is not registered in the United States and, consequently, is not subject to the regulations of that country governing the preparation of research and the independence of analysts. This report is distributed solely to major US institutional investors, in reliance on the exemption from registration provided by Rule 15a-6 of the US Securities Exchange Act of 1934, as amended (the "Exchange Act"), and interpretations of this made by the US Securities Exchange Commission.

Major US Institutional Investors. This report will be distributed to "major US institutional investors", as defined by Rule 15a-6 of the US Securities Exchange Commission and of the US Securities Exchange Act of 1934.

Notes and Reports History

Date of report	Recommendation	Price (EUR)	Target price (EUR)	Period of validity	Reason for report	Analyst
03-May-2024	n.a.	1.75	n.a.	n.a.	12m Results 2023 - Estimates downgrade	Luis Esteban Arribas, CESGA
02-Nov-2023	n.a.	2.06	n.a.	n.a.	6m Results 2023	Luis Esteban Arribas, CESGA
20-Jul-2023	n.a.	2.04	n.a.	n.a.	Important news - Estimates upgrade	Luis Esteban Arribas, CESGA
12-Jun-2023	n.a.	2.14	n.a.	n.a.	Small & Micro Caps (Spain)	David López Sánchez
18-May-2023	n.a.	2.06	n.a.	n.a.	Estimates upgrade	Luis Esteban Arribas, CESGA
10-May-2023	n.a.	2.00	n.a.	n.a.	Important news	Luis Esteban Arribas, CESGA
04-May-2023	n.a.	1.84	n.a.	n.a.	12m Results 2022	Luis Esteban Arribas, CESGA
31-Oct-2022	n.a.	1.47	n.a.	n.a.	6m Results 2022 - Estimates downgrade	Luis Esteban Arribas, CESGA
14-Jul-2022	n.a.	1.46	n.a.	n.a.	Important news	Alfredo Echevarría Otegui
02-May-2022	n.a.	1.70	n.a.	n.a.	12m Results 2021	Alfredo Echevarría Otegui
29-Oct-2021	n.a.	1.64	n.a.	n.a.	6m Results 2021	Alfredo Echevarría Otegui
02-Sep-2021	n.a.	1.70	n.a.	n.a.	Important news	Ana Isabel González García, CIIA
25-Jun-2021	n.a.	1.85	n.a.	n.a.	Important news	Ana Isabel González García, CIIA
05-May-2021	n.a.	2.17	n.a.	n.a.	12m Results 2020 - Estimates downgrade	Ana Isabel González García, CIIA
03-Nov-2020	n.a.	1.58	n.a.	n.a.	6m Results 2020	Ana Isabel González García, CIIA
16-Oct-2020	n.a.	1.56	n.a.	n.a.	Initiation of Coverage	Ana Isabel González García, CIIA

